Jan 13,2019

Sichuan Tiangui Animal Products Processing Factory, located in Shehong Meifeng Industrial Park, has received frequent good news. After the new technology of injection-grade heparin sodium bioenzymatic preparation in the factory passed the appraisal and certification of project results of Sichuan Science and Technology Department on April 8, representatives of Pfizer Company of the United States and the head of Nanjing Jianyou Pharmaceutical Company came to Tiangui Animal Products Processing Factory on April 11 to inspect and discuss cooperation matters. Sichuan Tiangui Animal Products Processing Factory is a private enterprise founded more than 10 years ago by Cai Tiangui, a Shehong native. The enterprise mainly uses the small intestine of live pigs as raw materials to produce heparin sodium and supplies it to domestic pharmaceutical companies. The pharmaceutical companies also transferred it to large foreign companies. In 2008, the sales volume of crude products reached more than 1000 kilograms. Heparin sodium is a natural polysaccharide substance extracted from biological raw materials. It is a mucopolysaccharide sulfate anticoagulant. It is clinically effective for cardiovascular system, respiratory system, liver, kidney disease, ulcerative colitis, constipation, and burns. It has a unique effect on arteriovenous thrombosis and blood plugs, and also has a significant effect on anti-cancer. The selling price of crude heparin sodium in China ranges from 12000 yuan to 15000 yuan per kilogram, while that of fine products is above 30000 yuan. Heparin sodium is recognized as "biological gold" in the world ". For more than 10 years, the factory has been employing university biology experts and professors to guide the production technology. The supply of heparin sodium products has been in short supply. It has established a good supply relationship with Nanjing Jianyou biochemical company and Chengdu Dongfeng biochemical company for a long time. Through these companies, the products are exported to the United States, France and other European and American countries and Southeast Asia. On April 8, Tiangui Animal Products Processing Factory injection grade heparin sodium bio-enzymatic preparation of new technology by the Sichuan Provincial Science and Technology Department product achievement appraisal certification, certification said: "The product has reached the Chinese Pharmacopoeia heparin sodium quality standards, by a number of customers trial has been recognized; the project development has reached the domestic advanced level; the process has green manufacturing characteristics, in line with the current environmental protection requirements. It is recommended to further increase industrial production." On April 11, Ms. Giaapleps, a representative of Pfizer, said after a detailed inspection of the production environment, production process and products of Tiangui livestock products processing plant: the production environment here is good, the production process meets the requirements of the United States, and she is satisfied with the product quality. she will further establish a long-term supply and marketing relationship with the plant, report the situation after returning home, and is expected to become an investment partner of the company.